Roche’s Announcement Regarding Enspryng (FDA Approval for Thyroid Eye Disease)

TOKYO, October 16, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release today regarding Enspryng^® (satralizumab), stating that the U.S. Food and Drug Administration (FDA) has approved Enspryng for the treatment of thyroid eye disease (TED).

Please refer to the link below for details of the media release:

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

https://www.roche.com/media/releases/med-cor-2026-10-16

Trademarks used or mentioned in this release are protected by laws.